North Coast Current

Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810

OsideNews • July 8, 2019

Treatment of Ornithine Transcarbamylase (OTC) Deficiency San Diego CA—Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization...

Arcturus Therapeutics to Present Data for ARCT-810 and the Arcturus mRNA + LUNAR Technology Platform

OsideNews • May 21, 2019

Presentation will take place at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics San Diego CA— Arcturus Therapeutics Ltd. (NASDAQ: ARCT) (the “Company”), a leading messenger...

Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency

OsideNews • January 8, 2019

San Diego CA— Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, liver and respiratory diseases...